Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
doi: 10.3389/fendo.2022.1033479 Received 31 August 2022 Accepted 27 October 2022 Published 17 November 2022 Volume 13 - 2022 Edited by Jianbo Zhou, Beijing Tongren Hospital, Capital Medical University, China Reviewed by Finbarr P
3 Follow-up data from the SURMOUNT-4 trial shows the weight loss is maintained at 88 weeks with continued use
to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus and established cardiovascular disease
In younger people with diabetes ( 10%) weight loss and weight loss early in the course of type 2 diabetes increase the chance of remission of disease [50]
Revista Mackenzie de Educao Fsica e Esporte 2009, 8 (1): 135-145 4
US$ 24.84
US$ 23.83
:max_bytes(150000):strip_icc()/GettyImages-2212535773-5a5ac4d1b1be49bea85e1e10905adaf7.jpg)
US$ 29.34
US$ 21.98
